Article Text

Download PDFPDF
Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus
  1. M D Köller1,
  2. E Templ2,
  3. M Riedl2,
  4. M Clodi2,
  5. O Wagner3,
  6. J S Smolen1,
  7. A Luger2
  1. 1Clinic for Internal Medicine III, Department of Rheumatology, University of Vienna, Austria
  2. 2Clinic for Internal Medicine III, Department of Endocrinology and Metabolism, University of Vienna, Austria
  3. 3Institute of Clinical Chemistry and Laboratory Diagnostic, University of Vienna, Austria
  1. Correspondence to:
    Dr M D Köller
    Department of Internal Medicine III, Division of Rheumatology, General Hospital, Währinger Gürtel 18–20, A-1090 Vienna, Austria; Marcus.Koellermeduniwien.ac.at

Abstract

Objectives: To determine whether hormonal dysfunction involving the hypothalamic-pituitary-adrenal (HPA) axis, prolactin (PRL) secretion, and sex hormone status contribute to development of systemic lupus erythematosus (SLE).

Methods: 11 patients with SLE and 9 healthy controls were tested for their total anterior pituitary gland reserve by simultaneous injection of corticotropin-, growth hormone- (GH), thyrotropin-, and gonadotropin-releasing hormone (GnRH). Serum concentrations of adrenocorticotropin (ACTH), cortisol, GH, thyroid stimulating hormone (TSH), PRL, luteinising hormone (LH), and follicle stimulating hormone (FSH) were measured at baseline and after injection. Baseline values of oestradiol, testosterone, and thyroxine were determined.

Results: Basal and stimulated serum concentrations of ACTH, cortisol, GH, and PRL were similar in both groups. In contrast, despite similar basal thyroxine levels the TSH response to TRH was significantly higher in patients than in controls. LH and FSH levels in premenopausal female patients of both groups were identical. In contrast, two of the three male patients were hypogonadal without compensatory increases of basal LH and FSH levels, but they retained excessive stimulatory capacity in response to GnRH.

Conclusion: No significant alteration of the HPA axis was found in patients with SLE, which is inadequate in view of the continuing inflammation. GH and PRL secretion were normal. The pituitary-thyroid and pituitary-gonadal axes were affected in patients with newly diagnosed, untreated SLE.

  • ACTH, adrenocorticotropin
  • CRH, corticotropin-releasing hormone
  • CV, coefficient of variation
  • DHEA, dehydroepiandrosterone
  • ECLAM, European Consensus Lupus Activity Measurement
  • FSH, follicle stimulating hormone
  • GH, growth hormone
  • GHRH, growth hormone-releasing hormone
  • GnRH, gonadotropin-releasing hormone
  • HC, healthy controls
  • HPA, hypothalamic-pituitary-adrenal
  • IL, interleukin
  • LH, luteinising hormone
  • PRL, prolactin
  • RA, rheumatoid arthritis
  • SLE, systemic lupus erythematosus
  • SLEDAI, SLE Disease Activity Index
  • T4, thyroxine
  • TNF, tumour necrosis factor
  • TRH, thyrotropin-releasing hormone
  • TSH, thyroid stimulating hormone
  • systemic lupus erythematosus
  • pituitary glands
  • endocrine function
  • hypogonadism

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes